CheckMate914
Por um escritor misterioso
Descrição
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - The Lancet
ScienceLink on X: #Nivolumab #Ipilimumab #CheckMate914 #ScienceLink CCR localizado: Nivolumab + ipilimumab no alcanzaron objetivo primario de SLE, estudio CheckMate-914 / X
Ziad Bakouny, MD, MSc on X: Dr. @motzermd with an important presentation of #CHECKMATE914 Part A subgroup analyses. @ASCO #ASCO23 While the overall trial showed no improved outcomes with the combination of
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma
CheckMate 914 Archives
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - The Lancet
A trial of nivolumab with or without ipilimumab after surgery for kidney cancer (CheckMate 914)
EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial - The Lancet
de
por adulto (o preço varia de acordo com o tamanho do grupo)
